Vanadium compounds for treating cancer

Abstract

The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

What is claimed is:  
     
       1. A compound of formula II: 
       wherein                    
       R and R 1  are each independently H (C1-C3)alkyl, halogen, (C1-C3)alkoxy, halo(C1-C3)alkyl, cyano, (C2-C6)alkanoyloxy or nitro;  
       X and X 1  are each OH 2 ; or taken together X and X 1  form a N,N-bidentate selected from the group consisting of N,N-bipyridine, N,N-bipyrimidine, and N,N-phenanthroline, wherein the N,N-bidentate can be substituted with up to two groups that are independently (C1-C3) alkyl, halogen, (C1-C3) alkoxy, halo (C1-C3) alkyl, cyano, (C2-C6) alkanoyloxy or nitro; and  
       Y is OSO 3 ;  
       or a pharmaceutically acceptable salt thereof.  
     
     
       2. The compound of  claim 1 , wherein R and R 1  are methyl. 
     
     
       3. The compound of  claim 1 , wherein the compound is                    
     
     
       4. The compound of  claim 1 , wherein the compound is                    
     
     
       5. A compound of formula                    
       a pharmaceutically acceptable salt thereof.  
     
     
       6. A compound of formula                    
       a pharmaceutically acceptable salt thereof.  
     
     
       7. A method for treating leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, testicular cancer, brain tumor, breast cancer, or prostate cancer, in a mammal comprising administering to said mammal an effective amount of                    
     
     
       8. A method for treating leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, testicular cancer, brain tumor, breast cancer, or prostate cancer, in a mammal comprising administering to said mammal an effective amount of a compound of formula II:                    
       wherein  
       R and R 1  are each independently H, (C1-C3)alkyl, halogen, (C1-C3)alkoxy, halo(C1-C3)alkyl, cyano, (C2-C6)alkanoyloxy or nitro;  
       X and X 1  are each independently OH 2 ; X is OH 2  and no ligand is present on X 1 ; or taken together X and X 1  form a N,N-bidentate selected from the group consisting of N,N-bipyridine, N,N-bipyrimidine, and N,N-phenanthroline, wherein the N,N-bidentate can be substituted with up to two groups that are independently (C1-C3) alkyl, halogen (C1-C3) alkoxy, halo (C1-C3) alkyl, cyano, (C2-C6) alkanoyloxy or nitro; and  
       Y is OH 2  or OSO 3 ; or  
       a pharmaceutically acceptable salt thereof.  
     
     
       9. The method of  claim 8 , wherein the compound is                    
     
     
       10. A method for treating leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, testicular cancer, brain tumor, breast cancer, or prostate cancer, in a mammal comprising administering to said mammal an effective amount of a compound of formula                    
       a pharmaceutically acceptable salt thereof.  
     
     
       11. A pharmaceutical composition comprising a compound of formula II:                    
       wherein  
       R and R 1  are each independently H, (C1-C3)alkyl, halogen, (C1-C3)alkoxy, halo(C1-C3)alkyl, cyano, (C2-C6)alkanoyloxy or nitro;  
       X and X 1  are each independently OH 2 , X is OH 2  and no ligand is present on X 1 ; or taken together X and X 1  form a N,N-bidentate selected from the group consisting of N,N-bipyridine, N,N-bipyrimidine, and N,N-phenanthroline, wherein the N,N-bidentate can be substituted with up to two groups that are independently (C1-C3) alkyl, halogen, (C1-C3) alkoxy, halo (C1-C3) alkyl, cyano, (C2-C6) alkanoyloxy or nitro; and  
       Y is OH 2  or OSO 3 ; or  
       a pharmaceutically acceptable salt thereof; and  
       a pharmaceutically acceptable carrier.  
     
     
       12. The pharmaceutical composition of  claim 11 , wherein the compound is                    
     
     
       13. A pharmaceutical composition comprising a compound of formula                    
       a pharmaceutically acceptable salt thereof; and  
       a pharmaceutically acceptable carrier.  
     
     
       14. A pharmaceutical composition comprising a compound of formula                    
       a pharmaceutically acceptable salt thereof; and  
       a pharmaceutically acceptable carrier.  
     
     
       15. The compound of  claim 1 , wherein the N,N-bidentate ligand is substituted with at least one methyl. 
     
     
       16. A compound of formula II: 
       wherein                    
       R and R 1  are each independently H, (C1-C3)alkyl, halogen, (C1-C3)alkoxy, halo(C1-C3)alkyl, cyano, (C2-C6)alkanoyloxy or nitro;  
       X is OH 2  and no ligand is present on X 1 ; and  
       Y is OH 2 ;  
       or a pharmaceutically acceptable salt thereof.  
     
     
       17. The compound of  claim 16 , wherein R and R 1  are methyl. 
     
     
       18. The compound of  claim 16 , wherein the compound is